These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 25930981

  • 1. Renal formulas pretreated with medications alters the nutrient profile.
    Taylor JM, Oladitan L, Carlson S, Hamilton-Reeves JM.
    Pediatr Nephrol; 2015 Oct; 30(10):1815-23. PubMed ID: 25930981
    [Abstract] [Full Text] [Related]

  • 2. Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency.
    Thompson K, Flynn J, Okamura D, Zhou L.
    J Ren Nutr; 2013 Sep; 23(5):333-9. PubMed ID: 23707305
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nutritional management of hyperkalemic infants with chronic kidney disease, using adult renal formulas.
    Hobbs DJ, Gast TR, Ferguson KB, Bunchman TE, Barletta GM.
    J Ren Nutr; 2010 Mar; 20(2):121-6. PubMed ID: 19853475
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.
    Georgianos PI, Liampas I, Kyriakou A, Vaios V, Raptis V, Savvidis N, Sioulis A, Liakopoulos V, Balaskas EV, Zebekakis PE.
    Int Urol Nephrol; 2017 Dec; 49(12):2217-2221. PubMed ID: 29027620
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pretreatment of infant formula with sodium polystyrene sulfonate : focus on optimal amount and contact time.
    Cameron JC, Kennedy D, Feber J, Wong E, Geier P, Vaillancourt R.
    Paediatr Drugs; 2013 Feb; 15(1):43-8. PubMed ID: 23329388
    [Abstract] [Full Text] [Related]

  • 9. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study.
    Hagan AE, Farrington CA, Wall GC, Belz MM.
    Clin Nephrol; 2016 Jan; 85(1):38-43. PubMed ID: 26587776
    [Abstract] [Full Text] [Related]

  • 10. Treatment of pediatric hyperkalemia with sodium polystyrene sulfonate.
    Lee J, Moffett BS.
    Pediatr Nephrol; 2016 Nov; 31(11):2113-7. PubMed ID: 27215929
    [Abstract] [Full Text] [Related]

  • 11. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kanoh H.
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [Abstract] [Full Text] [Related]

  • 12.
    ; 2006 Jun. PubMed ID: 29999809
    [Abstract] [Full Text] [Related]

  • 13. Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.
    Nakayama Y, Ueda K, Yamagishi SI, Sugiyama M, Yoshida C, Kurokawa Y, Nakamura N, Moriyama T, Kodama G, Minezaki T, Ito S, Nagata A, Taguchi K, Yano J, Kaida Y, Shibatomi K, Fukami K.
    Clin Exp Nephrol; 2018 Feb; 22(1):35-44. PubMed ID: 28421299
    [Abstract] [Full Text] [Related]

  • 14. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K, Kakuta H.
    Eur J Pharmacol; 2015 Nov 05; 766():129-34. PubMed ID: 26452517
    [Abstract] [Full Text] [Related]

  • 15. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C, Roe K, Lehman E, Verma N.
    Nephron Clin Pract; 2013 Nov 05; 123(1-2):61-6. PubMed ID: 23774446
    [Abstract] [Full Text] [Related]

  • 16. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
    Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, Vallée M, Savoie M, Perreault S, Laurin LP, Pichette V, Lafrance JP.
    Clin J Am Soc Nephrol; 2015 Dec 07; 10(12):2136-42. PubMed ID: 26576619
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.
    Mistry M, Shea A, Giguère P, Nguyen ML.
    Ann Pharmacother; 2016 Jun 07; 50(6):455-62. PubMed ID: 27048188
    [Abstract] [Full Text] [Related]

  • 18. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M.
    Kidney Int; 2006 Feb 07; 69(3):531-7. PubMed ID: 16395276
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S, Fröschl B, Hiebinger C, Zsifkovits J.
    Ann Nutr Metab; 2011 Oct 07; 58(4):315-9. PubMed ID: 21986491
    [Abstract] [Full Text] [Related]

  • 20. [Modelling of phosphorus transfers during haemodialysis].
    Chazot G, Lemoine S, Juillard L.
    Nephrol Ther; 2017 Apr 07; 13 Suppl 1():S89-S93. PubMed ID: 28577749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.